Emotion and Motivation in Patients With Psychosis
Study Details
Study Description
Brief Summary
Anhedonia and avolition reflect emotional and motivational disorders, respectively. However, if these disorders play a major role in the symptomatology of schizophrenia, their mechanisms remain poorly understood, and existing treatments are inefficient on these symptoms. The literature suggests that the impairment does not concern emotion or motivation per se, but rather their influence on cognition. This project aims at using recent advances in the fundamental domain to better understand the cognitive and neuronal mechanisms of the patients' alterations, and especially how emotion and motivation influence cognition in schizophrenia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Sham Comparator: Healthy volunteers Healthy volunteers |
Other: Electroencephalogram
electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
Behavioral: Cognitive tasks
- clinical scales and subjective assessments of emotional and motivational stimuli
Behavioral: subjective evaluation scales
- clinical scales and subjective assessments of emotional and motivational stimuli
|
| Experimental: Patients with schizophrenia Patients with schizophrenia |
Other: Electroencephalogram
electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
Behavioral: Cognitive tasks
- clinical scales and subjective assessments of emotional and motivational stimuli
Behavioral: subjective evaluation scales
- clinical scales and subjective assessments of emotional and motivational stimuli
|
Outcome Measures
Primary Outcome Measures
- Change in the amplitude of the CNV (Contingent Negative Variation) as a function of the primer displayed on the screen [During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)]
Before each cognitive trial a primer will be displayed, which will be either neutral or convey emotion or motivation. The investigators will check whether this primer affects the subjects preparation by measuring the CNV, which is an evoked potential recorded with electroencephalography, and indexing preparatory effort.
Secondary Outcome Measures
- Change in the amplitude of the LPP (Late Positive Potential) as a function of the primer displayed on the screen [During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)]
The investigators will check whether primers affect the subjects attention by measuring the LPP, which is an evoked potential recorded with electroencephalography, and indexing sustained attention.
Eligibility Criteria
Criteria
Inclusion Criteria:
- diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia
Exclusion Criteria:
-
addiction problem
-
invalidating visual sensory problems
-
neurological history
-
for the healthy volunteers: psychiatric history
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Unité INSERM 1114 | Strasbourg | France | 67091 |
Sponsors and Collaborators
- University Hospital, Strasbourg, France
- Institut National de la Santé Et de la Recherche Médicale, France
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 6152